Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.

Redondo M, Palomo V, Brea J, Pérez DI, Martín-Álvarez R, Pérez C, Paúl-Fernández N, Conde S, Cadavid MI, Loza MI, Mengod G, Martínez A, Gil C, Campillo NE.

ACS Chem Neurosci. 2012 Oct 17;3(10):793-803. doi: 10.1021/cn300105c. Epub 2012 Aug 8.

2.

Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.

Redondo M, Brea J, Perez DI, Soteras I, Val C, Perez C, Morales-García JA, Alonso-Gil S, Paul-Fernandez N, Martin-Alvarez R, Cadavid MI, Loza MI, Perez-Castillo A, Mengod G, Campillo NE, Martinez A, Gil C.

J Med Chem. 2012 Apr 12;55(7):3274-84. doi: 10.1021/jm201720d. Epub 2012 Mar 16.

PMID:
22385507
3.

Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis.

González-García C, Bravo B, Ballester A, Gómez-Pérez R, Eguiluz C, Redondo M, Martínez A, Gil C, Ballester S.

Br J Pharmacol. 2013 Oct;170(3):602-13. doi: 10.1111/bph.12308.

4.

Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors.

Castaño T, Wang H, Campillo NE, Ballester S, González-García C, Hernández J, Pérez C, Cuenca J, Pérez-Castillo A, Martínez A, Huertas O, Gelpí JL, Luque FJ, Ke H, Gil C.

ChemMedChem. 2009 May;4(5):866-76. doi: 10.1002/cmdc.200900043.

5.

Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation.

Guo J, Watson A, Kempson J, Carlsen M, Barbosa J, Stebbins K, Lee D, Dodd J, Nadler SG, McKinnon M, Barrish J, Pitts WJ.

Bioorg Med Chem Lett. 2009 Apr 1;19(7):1935-8. doi: 10.1016/j.bmcl.2009.02.060. Epub 2009 Feb 21.

PMID:
19272774
6.

PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury.

Paterniti I, Mazzon E, Gil C, Impellizzeri D, Palomo V, Redondo M, Perez DI, Esposito E, Martinez A, Cuzzocrea S.

PLoS One. 2011 Jan 31;6(1):e15937. doi: 10.1371/journal.pone.0015937.

7.

PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.

Mestre L, Redondo M, Carrillo-Salinas FJ, Morales-García JA, Alonso-Gil S, Pérez-Castillo A, Gil C, Martínez A, Guaza C.

Br J Pharmacol. 2015 Sep;172(17):4277-90. doi: 10.1111/bph.13192. Epub 2015 Jul 14.

8.

Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities.

Redondo M, Soteras I, Brea J, González-García A, Cadavid MI, Loza MI, Martinez A, Gil C, Campillo NE.

Eur J Med Chem. 2013;70:781-8. doi: 10.1016/j.ejmech.2013.10.035. Epub 2013 Oct 22.

PMID:
24239625
9.

Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors.

Folcik VA, Smith T, O'Bryant S, Kawczak JA, Zhu B, Sakurai H, Kajiwara A, Staddon JM, Glabinski A, Chernosky AL, Tani M, Johnson JM, Tuohy VK, Rubin LL, Ransohoff RM.

J Neuroimmunol. 1999 Jun 1;97(1-2):119-28.

PMID:
10408965
10.

Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.

García AM, Brea J, Morales-García JA, Perez DI, González A, Alonso-Gil S, Gracia-Rubio I, Ros-Simó C, Conde S, Cadavid MI, Loza MI, Perez-Castillo A, Valverde O, Martinez A, Gil C.

J Med Chem. 2014 Oct 23;57(20):8590-607. doi: 10.1021/jm501090m. Epub 2014 Oct 8.

PMID:
25264825
11.

Effect of phosphodiesterase 7 inhibitor ASB16165 on development and function of cytotoxic T lymphocyte.

Kadoshima-Yamaoka K, Murakawa M, Goto M, Tanaka Y, Inoue H, Murafuji H, Hayashi Y, Nagahira K, Miura K, Nakatsuka T, Chamoto K, Fukuda Y, Nishimura T.

Int Immunopharmacol. 2009 Jan;9(1):97-102. doi: 10.1016/j.intimp.2008.10.005. Epub 2008 Nov 6.

PMID:
18992850
12.

Discovery of 2-(cyclopentylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as a new series of potent phosphodiesterase 7 inhibitors.

Kawai K, Endo Y, Asano T, Amano S, Sawada K, Ueo N, Takahashi N, Sonoda Y, Nagai M, Kamei N, Nagata N.

J Med Chem. 2014 Dec 11;57(23):9844-54. doi: 10.1021/jm5008215. Epub 2014 Nov 19.

PMID:
25383422
13.

Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation.

Banerjee A, Yadav PS, Bajpai M, Sangana RR, Gullapalli S, Gudi GS, Gharat LA.

Bioorg Med Chem Lett. 2012 May 1;22(9):3223-8. doi: 10.1016/j.bmcl.2012.03.025. Epub 2012 Mar 23.

PMID:
22487174
14.
15.

Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.

Cabranes A, Venderova K, de Lago E, Fezza F, Sánchez A, Mestre L, Valenti M, García-Merino A, Ramos JA, Di Marzo V, Fernández-Ruiz J.

Neurobiol Dis. 2005 Nov;20(2):207-17.

PMID:
16242629
16.

Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis.

Reyes-Irisarri E, Sánchez AJ, García-Merino JA, Mengod G.

J Neuropathol Exp Neurol. 2007 Oct;66(10):923-31.

17.

New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders.

Safavi M, Baeeri M, Abdollahi M.

Expert Opin Drug Discov. 2013 Jun;8(6):733-51. doi: 10.1517/17460441.2013.787986. Epub 2013 Apr 9. Review.

PMID:
23570245
18.

Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.

Vergne F, Bernardelli P, Lorthiois E, Pham N, Proust E, Oliveira C, Mafroud AK, Royer F, Wrigglesworth R, Schellhaas J, Barvian M, Moreau F, Idrissi M, Tertre A, Bertin B, Coupe M, Berna P, Soulard P.

Bioorg Med Chem Lett. 2004 Sep 20;14(18):4607-13.

PMID:
15324874
19.

Synthesis and evaluation of quinazoline derivatives as phosphodiesterase 7 inhibitors.

Sánchez AI, Martínez-Barrasa V, Burgos C, Vaquero JJ, Alvarez-Builla J, Terricabras E, Segarra V.

Bioorg Med Chem. 2013 Apr 15;21(8):2370-8. doi: 10.1016/j.bmc.2013.01.067. Epub 2013 Feb 5.

PMID:
23454131
20.

Discovery and SAR study of 2-(4-pyridylamino)thieno[3,2-d]pyrimidin-4(3H)-ones as soluble and highly potent PDE7 inhibitors.

Endo Y, Kawai K, Asano T, Amano S, Asanuma Y, Sawada K, Ogura K, Nagata N, Ueo N, Takahashi N, Sonoda Y, Kamei N.

Bioorg Med Chem Lett. 2015 Feb 1;25(3):649-53. doi: 10.1016/j.bmcl.2014.11.090. Epub 2014 Dec 6.

PMID:
25529739
Items per page

Supplemental Content

Write to the Help Desk